Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Retooling The Sales Force Remains A Work In Progress

Executive Summary

Pharmaceutical sales reps may not relish the thought, but they could play leading roles in a Hollywood epic called 'The Incredible Shrinking Sales Force.' Between 2005 and the third quarter of 2009, the number of reps industry wide in the U.S. fell from 101,818 to 81,780, a 19.7 percent decline, according to SDI Health
Advertisement

Related Content

Out With Experimentation, ZS Sees New Commercial Models Settling In
Pharma Promo Spending Mostly Level Despite Challenges
Pharma's 2010 Promotional Budget: Fewer Reps But Same Dollars
Pharma's 2010 Promotional Budget: Fewer Reps But Same Dollars
InVentiv Sees More Opportunities To Serve Pharma As Private Vs. Public Company
Merck Names Ken Frazier President
AHRQ Considers Academic Detailing To Distribute CER Findings
AHRQ Considers Academic Detailing To Distribute CER Findings
Ending the Arms Race: Ten Priorities for Fixing the Commercial Model

Topics

Advertisement
UsernamePublicRestriction

Register

PS051855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel